Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Western Equine Encephalitis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Western Equine Encephalitis - Pipeline Review, H2 2016, provides an overview of the Western Equine Encephalitis (Infectious Disease) pipeline landscape. Western equine encephalitis is a disease that is spread to humans by infected mosquitoes. Western equine encephalitis is caused by the western equine encephalitis virus, an arbovirus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Western Equine Encephalitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Western Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Western Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Western Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 4 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively. Western Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Western Equine Encephalitis (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Western Equine Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Western Equine Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Western Equine Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Western Equine Encephalitis (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Western Equine Encephalitis (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Western Equine Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Western Equine Encephalitis Overview 6 Therapeutics Development 7 Pipeline Products for Western Equine Encephalitis - Overview 7 Pipeline Products for Western Equine Encephalitis - Comparative Analysis 8 Western Equine Encephalitis - Therapeutics under Development by Companies 9 Western Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes 10 Western Equine Encephalitis - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Western Equine Encephalitis - Products under Development by Companies 13 Western Equine Encephalitis - Products under Investigation by Universities/Institutes 14 Western Equine Encephalitis - Companies Involved in Therapeutics Development 15 Akshaya Bio Inc 15 Altravax Inc 16 EpiVax Inc 17 H&P Labs Inc 18 Profectus BioSciences Inc 19 Western Equine Encephalitis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 DEF-201 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 equine encephalitis (trivalent) vaccine - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 equine encephalitis vaccine - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 equine encephalitis vaccine - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Vaccine for Western Equine Encephalitis - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Westrern Equine Encephalitis Virus Vaccine - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Western Equine Encephalitis - Dormant Projects 36 Western Equine Encephalitis - Product Development Milestones 37 Featured News & Press Releases 37 Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables
Number of Products under Development for Western Equine Encephalitis, H2 2016 7 Number of Products under Development for Western Equine Encephalitis - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Western Equine Encephalitis - Pipeline by Akshaya Bio Inc, H2 2016 15 Western Equine Encephalitis - Pipeline by Altravax Inc, H2 2016 16 Western Equine Encephalitis - Pipeline by EpiVax Inc, H2 2016 17 Western Equine Encephalitis - Pipeline by H&P Labs Inc, H2 2016 18 Western Equine Encephalitis - Pipeline by Profectus BioSciences Inc, H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Stage and Target, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 28 Western Equine Encephalitis - Dormant Projects, H2 2016 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.